MYMETICS REPORTS PRECLINICAL RESULTS FOR HIV VACCINE CANDIDATE

A A

Mymetics has announced preliminary findings from preclinical studies of the company's HIV-AIDS prophylactic vaccine candidate.

Analysis of blood samples taken six weeks post-vaccination with virosome-gp41 peptides have revealed the presence of anti-gp41 antibodies (IgG and IgA), confirming previous data from rabbit models. The immunization protocols will continue through early September 2006 in order to detect the production of secretory IgA antibodies in mucosal tissues, the primary route of infection and a first line of defense against HIV.